For the full-year 2023, the Company anticipates total Galafold revenue growth between 12 and 17% at CER1 driven by continued underlying demand from both switch and treatment-naive patients, geographic expansion, label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan. Non-GAAP operating expense guidance for the full-year 2023 is $340 million to $360 million, driven by prudent expense management offset by continued investment in the global Galafold launch, AT-GAA clinical studies and pre-launch activities, in addition to certain non-recurring costs for manufacturing to support the global launch of AT-GAA4. The Company is on-track to achieve non-GAAP profitability2 in the second half of 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FOLD:
- Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
- Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
- Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
- Amicus reports ‘positive’ long-term data from Phase 3 study of AT-GAA
- Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference